SAINT I (Stroke - Acute Ischemic - NXY Treatment) a double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 [disufenton, Cerovive(Rm); AstraZeneca] in acute ischemic stroke
Latest Information Update: 10 Apr 2009
At a glance
- Drugs Disufenton (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SAINT-I
- 06 Oct 2005 New trial record.